We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IAG:LSEInternational Consolidated Airlines Group SA Analysis

Data as of 2026-03-14 - not real-time

£353.70

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

IAG trades at a **trailing P/E of just 5.9x**, far below the industry average of 29x, and the DCF model suggests a fair value of about £525, implying roughly 42% upside from the current £353 price. The balance sheet shows **£8.3bn in cash versus £14.3bn of debt**, yielding a high leverage ratio but a modest debt‑to‑equity of 188% and a robust **ROE of 48%**, indicating strong profit generation on equity. Cash conversion is healthy with operating cash flow of £6.6bn and free cash flow of £2.2bn, supporting a **2.37% dividend yield** and a low payout ratio of 15.5%, which suggests the dividend is sustainable.
Technical signals are mixed: the 20‑day SMA sits at £405, the price is below both the 20‑day and 50‑day averages, the RSI is in oversold territory at 33, while the MACD histogram remains negative, pointing to short‑term bearish momentum but potential for a rebound from the identified support at £343. Recent news highlights a strong 2025 earnings recovery and analyst consensus of a “buy” rating, reinforcing the fundamental upside despite the recent price wobble.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI suggesting price rebound potential
  • Support level at £343 providing downside cushion
  • Strong cash generation supporting near‑term stability

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation gap versus DCF fair value
  • Robust earnings growth and high ROE
  • Analyst consensus of buy and positive earnings narrative

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable dividend with low payout ratio
  • Global network diversification reducing geographic concentration
  • Long‑term industry recovery and improving demand outlook

Key Metrics & Analysis

Financial Health

Revenue Growth-0.80%
Profit Margin10.06%
P/E Ratio5.9
ROE48.54%
ROA7.36%
Debt/Equity187.87
P/B Ratio246.7
Op. Cash Flow£6.6B
Free Cash Flow£2.2B
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI32.8
Support£343.49
Resistance£464.28
MA 20£405.56
MA 50£416.09
MA 200£389.95
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value£525.56
Target Price£501.56
Upside/Downside41.80%
GradeUndervalued
TypeBlend
Dividend Yield2.37%

Risk Assessment

Beta0.58
Volatility47.95%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.